Myeloproliferative Disorders: Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE.Polycythemia Vera: A myeloproliferative disorder of unknown etiology, characterized by abnormal proliferation of all hematopoietic bone marrow elements and an absolute increase in red cell mass and total blood volume, associated frequently with splenomegaly, leukocytosis, and thrombocythemia. Hematopoiesis is also reactive in extramedullary sites (liver and spleen). In time myelofibrosis occurs.Primary Myelofibrosis: A de novo myeloproliferation arising from an abnormal stem cell. It is characterized by the replacement of bone marrow by fibrous tissue, a process that is mediated by CYTOKINES arising from the abnormal clone.Janus Kinase 2: A Janus kinase subtype that is involved in signaling from GROWTH HORMONE RECEPTORS; PROLACTIN RECEPTORS; and a variety of CYTOKINE RECEPTORS such as ERYTHROPOIETIN RECEPTORS and INTERLEUKIN RECEPTORS. Dysregulation of Janus kinase 2 due to GENETIC TRANSLOCATIONS have been associated with a variety of MYELOPROLIFERATIVE DISORDERS.Thrombocythemia, Essential: A clinical syndrome characterized by repeated spontaneous hemorrhages and a remarkable increase in the number of circulating platelets.Thrombocytosis: Increased numbers of platelets in the peripheral blood. (Dorland, 27th ed)Receptors, Thrombopoietin: Cell surface receptors that are specific for THROMBOPOIETIN. They signal through interaction with JANUS KINASES such as JANUS KINASE 2.Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative: A myelodysplastic/myeloproliferative disorder characterized by myelodysplasia associated with bone marrow and peripheral blood patterns similar to CHRONIC MYELOID LEUKEMIA, but cytogenetically lacking a PHILADELPHIA CHROMOSOME or bcr/abl fusion gene (GENES, ABL).Leukemia, Myelomonocytic, Chronic: A myelodysplastic-myeloproliferative disease characterized by monocytosis, increased monocytes in the bone marrow, variable degrees of dysplasia, but an absence of immature granulocytes in the blood.Splenomegaly: Enlargement of the spleen.Hematopoiesis, Extramedullary: The formation and development of blood cells outside the BONE MARROW, as in the SPLEEN; LIVER; or LYMPH NODES.Leukemia, Neutrophilic, Chronic: A rare myeloproliferative disorder that is characterized by a sustained, mature neutrophilic leukocytosis. No monocytosis, EOSINOPHILIA, or basophilia is present, nor is there a PHILADELPHIA CHROMOSOME or bcr-abl fusion gene (GENES, ABL).Leukemia, Myelogenous, Chronic, BCR-ABL Positive: Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.Leukemia, Myelomonocytic, Juvenile: A leukemia affecting young children characterized by SPLENOMEGALY, enlarged lymph nodes, rashes, and hemorrhages. Traditionally classed as a myeloproliferative disease, it is now considered a mixed myeloproliferative-mylelodysplastic disorder.Bone Marrow: The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells.Myelodysplastic Syndromes: Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.Hematopoietic Stem Cells: Progenitor cells from which all blood cells derive.Leukemia, Megakaryoblastic, Acute: An acute myeloid leukemia in which 20-30% of the bone marrow or peripheral blood cells are of megakaryocyte lineage. MYELOFIBROSIS or increased bone marrow RETICULIN is common.Granulocytes: Leukocytes with abundant granules in the cytoplasm. They are divided into three groups according to the staining properties of the granules: neutrophilic, eosinophilic, and basophilic. Mature granulocytes are the NEUTROPHILS; EOSINOPHILS; and BASOPHILS.Down Syndrome: A chromosome disorder associated either with an extra chromosome 21 or an effective trisomy for chromosome 21. Clinical manifestations include hypotonia, short stature, brachycephaly, upslanting palpebral fissures, epicanthus, Brushfield spots on the iris, protruding tongue, small ears, short, broad hands, fifth finger clinodactyly, Simian crease, and moderate to severe INTELLECTUAL DISABILITY. Cardiac and gastrointestinal malformations, a marked increase in the incidence of LEUKEMIA, and the early onset of ALZHEIMER DISEASE are also associated with this condition. Pathologic features include the development of NEUROFIBRILLARY TANGLES in neurons and the deposition of AMYLOID BETA-PROTEIN, similar to the pathology of ALZHEIMER DISEASE. (Menkes, Textbook of Child Neurology, 5th ed, p213)Fusion Proteins, bcr-abl: Translation products of a fusion gene derived from CHROMOSOMAL TRANSLOCATION of C-ABL GENES to the genetic locus of the breakpoint cluster region gene on chromosome 22. Several different variants of the bcr-abl fusion proteins occur depending upon the precise location of the chromosomal breakpoint. These variants can be associated with distinct subtypes of leukemias such as PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; and NEUTROPHILIC LEUKEMIA, CHRONIC.Megakaryocytes: Very large BONE MARROW CELLS which release mature BLOOD PLATELETS.Receptor, Fibroblast Growth Factor, Type 1: A fibroblast growth factor receptor with specificity for FIBROBLAST GROWTH FACTORS; HEPARAN SULFATE PROTEOGLYCAN; and NEURONAL CELL ADHESION MOLECULES. Several variants of the receptor exist due to multiple ALTERNATIVE SPLICING of its mRNA. Fibroblast growth factor receptor 1 is a tyrosine kinase that transmits signals through the MAP KINASE SIGNALING SYSTEM.Leukemia, Myeloid: Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites.Mutation: Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations.Polycythemia: An increase in the total red cell mass of the blood. (Dorland, 27th ed)Myelodysplastic-Myeloproliferative Diseases: Clonal myeloid disorders that possess both dysplastic and proliferative features but are not properly classified as either MYELODYSPLASTIC SYNDROMES or MYELOPROLIFERATIVE DISORDERS.Hepatomegaly: Enlargement of the liver.Translocation, Genetic: A type of chromosome aberration characterized by CHROMOSOME BREAKAGE and transfer of the broken-off portion to another location, often to a different chromosome.Hypereosinophilic Syndrome: A heterogeneous group of disorders with the common feature of prolonged eosinophilia of unknown cause and associated organ system dysfunction, including the heart, central nervous system, kidneys, lungs, gastrointestinal tract, and skin. There is a massive increase in the number of EOSINOPHILS in the blood, mimicking leukemia, and extensive eosinophilic infiltration of the various organs.Leukocytosis: A transient increase in the number of leukocytes in a body fluid.Chromosomes, Human, Pair 8: A specific pair of GROUP C CHROMOSOMES of the human chromosome classification.Budd-Chiari Syndrome: A condition in which the hepatic venous outflow is obstructed anywhere from the small HEPATIC VEINS to the junction of the INFERIOR VENA CAVA and the RIGHT ATRIUM. Usually the blockage is extrahepatic and caused by blood clots (THROMBUS) or fibrous webs. Parenchymal FIBROSIS is uncommon.Genes, abl: Retrovirus-associated DNA sequences (abl) originally isolated from the Abelson murine leukemia virus (Ab-MuLV). The proto-oncogene abl (c-abl) codes for a protein that is a member of the tyrosine kinase family. The human c-abl gene is located at 9q34.1 on the long arm of chromosome 9. It is activated by translocation to bcr on chromosome 22 in chronic myelogenous leukemia.Thrombopoietin: A humoral factor that stimulates the production of thrombocytes (BLOOD PLATELETS). Thrombopoietin stimulates the proliferation of bone marrow MEGAKARYOCYTES and their release of blood platelets. The process is called THROMBOPOIESIS.Leukemia, Myeloid, Acute: Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.Hematopoiesis: The development and formation of various types of BLOOD CELLS. Hematopoiesis can take place in the BONE MARROW (medullary) or outside the bone marrow (HEMATOPOIESIS, EXTRAMEDULLARY).Mutation, Missense: A mutation in which a codon is mutated to one directing the incorporation of a different amino acid. This substitution may result in an inactive or unstable product. (From A Dictionary of Genetics, King & Stansfield, 5th ed)Oncogene Proteins, Fusion: The GENETIC TRANSLATION products of the fusion between an ONCOGENE and another gene. The latter may be of viral or cellular origin.Hydroxyurea: An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.Chromosomes, Human, Pair 20: A specific pair of GROUP F CHROMOSOMES of the human chromosome classification.Blast Crisis: An advanced phase of chronic myelogenous leukemia, characterized by a rapid increase in the proportion of immature white blood cells (blasts) in the blood and bone marrow to greater than 30%.X Chromosome Inactivation: A dosage compensation process occurring at an early embryonic stage in mammalian development whereby, at random, one X CHROMOSOME of the pair is repressed in the somatic cells of females.Bipolar Disorder: A major affective disorder marked by severe mood swings (manic or major depressive episodes) and a tendency to remission and recurrence.Myelopoiesis: Formation of MYELOID CELLS from the pluripotent HEMATOPOIETIC STEM CELLS in the BONE MARROW via MYELOID STEM CELLS. Myelopoiesis generally refers to the production of leukocytes in blood, such as MONOCYTES and GRANULOCYTES. This process also produces precursor cells for MACROPHAGE and DENDRITIC CELLS found in the lymphoid tissue.Colony-Forming Units Assay: A cytologic technique for measuring the functional capacity of stem cells by assaying their activity.Chromosomes, Human, Pair 5: One of the two pairs of human chromosomes in the group B class (CHROMOSOMES, HUMAN, 4-5).Benzamides: BENZOIC ACID amides.Anemia, Refractory, with Excess of Blasts: Chronic refractory anemia with granulocytopenia, and/or thrombocytopenia. Myeloblasts and progranulocytes constitute 5 to 40 percent of the nucleated marrow cells.Bone Marrow Cells: Cells contained in the bone marrow including fat cells (see ADIPOCYTES); STROMAL CELLS; MEGAKARYOCYTES; and the immediate precursors of most blood cells.Platelet Count: The number of PLATELETS per unit volume in a sample of venous BLOOD.Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care. (Dictionary of Health Services Management, 2d ed)Bone Marrow Neoplasms: Neoplasms located in the bone marrow. They are differentiated from neoplasms composed of bone marrow cells, such as MULTIPLE MYELOMA. Most bone marrow neoplasms are metastatic.GATA1 Transcription Factor: A GATA transcription factor that is specifically expressed in hematopoietic lineages and plays an important role in the CELL DIFFERENTIATION of ERYTHROID CELLS and MEGAKARYOCYTES.Mental Disorders: Psychiatric illness or diseases manifested by breakdowns in the adaptational process expressed primarily as abnormalities of thought, feeling, and behavior producing either distress or impairment of function.Philadelphia Chromosome: An aberrant form of human CHROMOSOME 22 characterized by translocation of the distal end of chromosome 9 from 9q34, to the long arm of chromosome 22 at 22q11. It is present in the bone marrow cells of 80 to 90 per cent of patients with chronic myelocytic leukemia (LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE).Hydrops Fetalis: Abnormal accumulation of serous fluid in two or more fetal compartments, such as SKIN; PLEURA; PERICARDIUM; PLACENTA; PERITONEUM; AMNIOTIC FLUID. General fetal EDEMA may be of non-immunologic origin, or of immunologic origin as in the case of ERYTHROBLASTOSIS FETALIS.Leukemia: A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)Blood Cell Count: The number of LEUKOCYTES and ERYTHROCYTES per unit volume in a sample of venous BLOOD. A complete blood count (CBC) also includes measurement of the HEMOGLOBIN; HEMATOCRIT; and ERYTHROCYTE INDICES.Pyrimidines: A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates.PiperazinesHematologic Diseases: Disorders of the blood and blood forming tissues.Janus Kinases: A family of intracellular tyrosine kinases that participate in the signaling cascade of cytokines by associating with specific CYTOKINE RECEPTORS. They act upon STAT TRANSCRIPTION FACTORS in signaling pathway referred to as the JAK/STAT pathway. The name Janus kinase refers to the fact the proteins have two phosphate-transferring domains.Chromosomes, Human, X: The human female sex chromosome, being the differential sex chromosome carried by half the male gametes and all female gametes in humans.Anxiety Disorders: Persistent and disabling ANXIETY.DNA Mutational Analysis: Biochemical identification of mutational changes in a nucleotide sequence.Myeloid Progenitor Cells: Stem cells derived from HEMATOPOIETIC STEM CELLS. Derived from these myeloid progenitor cells are the MEGAKARYOCYTES; ERYTHROID CELLS; MYELOID CELLS; and some DENDRITIC CELLS.Mood Disorders: Those disorders that have a disturbance in mood as their predominant feature.Myeloid Cells: The classes of BONE MARROW-derived blood cells in the monocytic series (MONOCYTES and their precursors) and granulocytic series (GRANULOCYTES and their precursors).Point Mutation: A mutation caused by the substitution of one nucleotide for another. This results in the DNA molecule having a change in a single base pair.Chromosomes, Human, Pair 13: A specific pair of GROUP D CHROMOSOMES of the human chromosome classification.Karyotyping: Mapping of the KARYOTYPE of a cell.Protein-Tyrosine Kinases: Protein kinases that catalyze the PHOSPHORYLATION of TYROSINE residues in proteins with ATP or other nucleotides as phosphate donors.Gene Expression Regulation, Leukemic: Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in leukemia.Valine: A branched-chain essential amino acid that has stimulant activity. It promotes muscle growth and tissue repair. It is a precursor in the penicillin biosynthetic pathway.Proto-Oncogene Proteins: Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity.Erythroid Precursor Cells: The cells in the erythroid series derived from MYELOID PROGENITOR CELLS or from the bi-potential MEGAKARYOCYTE-ERYTHROID PROGENITOR CELLS which eventually give rise to mature RED BLOOD CELLS. The erythroid progenitor cells develop in two phases: erythroid burst-forming units (BFU-E) followed by erythroid colony-forming units (CFU-E); BFU-E differentiate into CFU-E on stimulation by ERYTHROPOIETIN, and then further differentiate into ERYTHROBLASTS when stimulated by other factors.Amino Acid Substitution: The naturally occurring or experimentally induced replacement of one or more AMINO ACIDS in a protein with another. If a functionally equivalent amino acid is substituted, the protein may retain wild-type activity. Substitution may also diminish, enhance, or eliminate protein function. Experimentally induced substitution is often used to study enzyme activities and binding site properties.Hematologic Neoplasms: Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.Cell Transformation, Neoplastic: Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.Receptor, Platelet-Derived Growth Factor beta: A PDGF receptor that binds specifically to the PDGF-B chain. It contains a protein-tyrosine kinase activity that is involved in SIGNAL TRANSDUCTION.Bone Marrow Transplantation: The transference of BONE MARROW from one human or animal to another for a variety of purposes including HEMATOPOIETIC STEM CELL TRANSPLANTATION or MESENCHYMAL STEM CELL TRANSPLANTATION.Receptors, Fibroblast Growth Factor: Specific molecular sites or structures on cell membranes that react with FIBROBLAST GROWTH FACTORS (both the basic and acidic forms), their analogs, or their antagonists to elicit or to inhibit the specific response of the cell to these factors. These receptors frequently possess tyrosine kinase activity.Splenectomy: Surgical procedure involving either partial or entire removal of the spleen.Neurofibromin 1: A protein found most abundantly in the nervous system. Defects or deficiencies in this protein are associated with NEUROFIBROMATOSIS 1, Watson syndrome, and LEOPARD syndrome. Mutations in the gene (GENE, NEUROFIBROMATOSIS 1) affect two known functions: regulation of ras-GTPase and tumor suppression.Chromosomes, Human, Pair 9: A specific pair of GROUP C CHROMSOMES of the human chromosome classification.Clone Cells: A group of genetically identical cells all descended from a single common ancestral cell by mitosis in eukaryotes or by binary fission in prokaryotes. Clone cells also include populations of recombinant DNA molecules all carrying the same inserted sequence. (From King & Stansfield, Dictionary of Genetics, 4th ed)Core Binding Factor Alpha 2 Subunit: A transcription factor that dimerizes with the cofactor CORE BINDING FACTOR BETA SUBUNIT to form core binding factor. It contains a highly conserved DNA-binding domain known as the runt domain. Runx1 is frequently mutated in human LEUKEMIAS.Signal Transduction: The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway.Diagnostic and Statistical Manual of Mental Disorders: Categorical classification of MENTAL DISORDERS based on criteria sets with defining features. It is produced by the American Psychiatric Association. (DSM-IV, page xxii)In Situ Hybridization, Fluorescence: A type of IN SITU HYBRIDIZATION in which target sequences are stained with fluorescent dye so their location and size can be determined using fluorescence microscopy. This staining is sufficiently distinct that the hybridization signal can be seen both in metaphase spreads and in interphase nuclei.Phenotype: The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment.Polymerase Chain Reaction: In vitro method for producing large amounts of specific DNA or RNA fragments of defined length and sequence from small amounts of short oligonucleotide flanking sequences (primers). The essential steps include thermal denaturation of the double-stranded target molecules, annealing of the primers to their complementary sequences, and extension of the annealed primers by enzymatic synthesis with DNA polymerase. The reaction is efficient, specific, and extremely sensitive. Uses for the reaction include disease diagnosis, detection of difficult-to-isolate pathogens, mutation analysis, genetic testing, DNA sequencing, and analyzing evolutionary relationships.Disease Models, Animal: Naturally occurring or experimentally induced animal diseases with pathological processes sufficiently similar to those of human diseases. They are used as study models for human diseases.Blood Platelets: Non-nucleated disk-shaped cells formed in the megakaryocyte and found in the blood of all mammals. They are mainly involved in blood coagulation.Sarcoma Viruses, Murine: A group of replication-defective viruses, in the genus GAMMARETROVIRUS, which are capable of transforming cells, but which replicate and produce tumors only in the presence of Murine leukemia viruses (LEUKEMIA VIRUS, MURINE).Chromosome Aberrations: Abnormal number or structure of chromosomes. Chromosome aberrations may result in CHROMOSOME DISORDERS.Receptors, Cytokine: Cell surface proteins that bind cytokines and trigger intracellular changes influencing the behavior of cells.Erythropoietin: Glycoprotein hormone, secreted chiefly by the KIDNEY in the adult and the LIVER in the FETUS, that acts on erythroid stem cells of the BONE MARROW to stimulate proliferation and differentiation.Antigens, CD34: Glycoproteins found on immature hematopoietic cells and endothelial cells. They are the only molecules to date whose expression within the blood system is restricted to a small number of progenitor cells in the bone marrow.Cell Proliferation: All of the processes involved in increasing CELL NUMBER including CELL DIVISION.Eosinophilia: Abnormal increase of EOSINOPHILS in the blood, tissues or organs.Spleen: An encapsulated lymphatic organ through which venous blood filters.Leukocyte Count: The number of WHITE BLOOD CELLS per unit volume in venous BLOOD. A differential leukocyte count measures the relative numbers of the different types of white cells.Retroviridae: Family of RNA viruses that infects birds and mammals and encodes the enzyme reverse transcriptase. The family contains seven genera: DELTARETROVIRUS; LENTIVIRUS; RETROVIRUSES TYPE B, MAMMALIAN; ALPHARETROVIRUS; GAMMARETROVIRUS; RETROVIRUSES TYPE D; and SPUMAVIRUS. A key feature of retrovirus biology is the synthesis of a DNA copy of the genome which is integrated into cellular DNA. After integration it is sometimes not expressed but maintained in a latent state (PROVIRUSES).Receptors, Erythropoietin: Cell surface proteins that bind erythropoietin with high affinity and trigger intracellular changes influencing the behavior of cells.Chromosome Disorders: Clinical conditions caused by an abnormal chromosome constitution in which there is extra or missing chromosome material (either a whole chromosome or a chromosome segment). (from Thompson et al., Genetics in Medicine, 5th ed, p429)Blood Cells: The cells found in the body fluid circulating throughout the CARDIOVASCULAR SYSTEM.Genetic Testing: Detection of a MUTATION; GENOTYPE; KARYOTYPE; or specific ALLELES associated with genetic traits, heritable diseases, or predisposition to a disease, or that may lead to the disease in descendants. It includes prenatal genetic testing.Moloney murine sarcoma virus: A replication-defective murine sarcoma virus (SARCOMA VIRUSES, MURINE) isolated from a rhabdomyosarcoma by Moloney in 1966.Mice, Inbred C57BLMice, Transgenic: Laboratory mice that have been produced from a genetically manipulated EGG or EMBRYO, MAMMALIAN.Receptor Protein-Tyrosine Kinases: A class of cellular receptors that have an intrinsic PROTEIN-TYROSINE KINASE activity.Erythropoiesis: The production of red blood cells (ERYTHROCYTES). In humans, erythrocytes are produced by the YOLK SAC in the first trimester; by the liver in the second trimester; by the BONE MARROW in the third trimester and after birth. In normal individuals, the erythrocyte count in the peripheral blood remains relatively constant implying a balance between the rate of erythrocyte production and rate of destruction.Base Sequence: The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence.Anemia, Refractory: A severe sometimes chronic anemia, usually macrocytic in type, that does not respond to ordinary antianemic therapy.Protein Kinase Inhibitors: Agents that inhibit PROTEIN KINASES.STAT5 Transcription Factor: A signal transducer and activator of transcription that mediates cellular responses to a variety of CYTOKINES. Stat5 activation is associated with transcription of CELL CYCLE regulators such as CYCLIN KINASE INHIBITOR P21 and anti-apoptotic genes such as BCL-2 GENES. Stat5 is constitutively activated in many patients with acute MYELOID LEUKEMIA.Flow Cytometry: Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake.Disease Progression: The worsening of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis.Depressive Disorder, Major: Marked depression appearing in the involution period and characterized by hallucinations, delusions, paranoia, and agitation.

*  JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science - Semantic Scholar
... are clonal hematopoietic stem-cell disorders, for many years the genetic basis for these disorders was elusive. A new era in ... Although it has long been known that the myeloproliferative neoplasms (MPN) polycythemia vera (PV), essential thrombocythemia ( ... MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort.. *Philip A Beer. , Peter J Campbell. , +11 authors ... Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders.. *Animesh Pardanani. , Brooke L ...
  https://www.semanticscholar.org/paper/JAK2-and-MPL-mutations-in-myeloproliferative-neopl-Kilpivaara-Levine/df782fb177dba7c3cc179d989f480136d6518270
*  Screening for Pulmonary Vascular Changes in Patients With Chronic Myeloproliferative Diseases - Full Text View - ClinicalTrials...
Myeloproliferative Disorders. Vascular Diseases. Cardiovascular Diseases. Lung Diseases. Respiratory Tract Diseases. Bone ... myeloproliferative disorders Echocardiography, spiroergometry, cardiac catheterization. Other: Echocardiography, spiroergometry ... and chronic myeloproliferative disorders (CMPD). MPD may cause PH through different mechanisms as: high cardiac output, ... Screening for Pulmonary Vascular Changes in Patients With Chronic Myeloproliferative Diseases. Resource links provided by NLM: ...
  https://clinicaltrials.gov/ct2/show/NCT01787162?term=%22High+Blood+Pressure%22&lup_s=01%2F26%2F2013&lup_d=14&show_rss=Y&sel_rss=mod14
*  Managing Myeloproliferative Neoplasms : A Case-Based Approach
... and also less common disorders such as systemic mast cell disease, hypereosinophilia, MPN/MBS overlap syndromes and atypical ... This book is an outstanding resource that includes a discussion of both classical myeloproliferative neoplasms, such as ... documenting examples and scenarios that will help you manage challenging clinical issues for patients with myeloproliferative ...
  http://ebooksmedicine.net/managing-myeloproliferative-neoplasms-a-case-based-approach4540
*  Myeloproliferative disorders: a paradox of in-vivo and in-vitro platelet function. | Journal of Clinical Pathology
A patient with features of a myeloproliferative disorder developed an acute multisystems illness and died. In-vitro platelet ... Myeloproliferative disorders: a paradox of in-vivo and in-vitro platelet function. ... Myeloproliferative disorders: a paradox of in-vivo and in-vitro platelet function. ...
  http://jcp.bmj.com/content/30/3/228
*  Providers - Myeloproliferative Disorders - BlueSelect All Copay 1457 - Lake Mary, FL | DocSpot
4 providers with an interest in myeloproliferative disorders and who accept BlueSelect All Copay 1457 near Lake Mary, FL. Find ... We found 4 providers with an interest in myeloproliferative disorders and who accept BlueSelect All Copay 1457 near Lake Mary, ... Relevant Interests: , myeloproliferative disorders. All Interests: Bone Marrow Exam, Brain Cancer, Sickle Cell Disease, Liver ... Relevant Interests: , myeloproliferative disorders. All Interests: Sickle Cell Disease, Liver Cancer, Skin Cancer, Oral Cancer ...
  https://www.docspot.com/d/FL/lake-mary/specialty-interest/myeloproliferative-disorders/blueselect-all-copay-1457.html
*  Myeloproliferative Disorders Support Group - Drugs.com
Ask questions and get answers about Myeloproliferative Disorders. Our support group helps people share their own experience. 10 ... Home › Q & A › Support Groups › Myeloproliferative Disorders. Join the 'Myeloproliferative Disorders' group to help and get ... Myeloproliferative Disorders - I was just diagnosed with ET. Platelet count at 650 with no symptoms?. Posted 20 Jun 2014 • 1 ... Our support group for Myeloproliferative Disorders has 3 questions and 10 members. Updated 20 Jun 2014. ...
  https://www.drugs.com/answers/support-group/myeloproliferative-disorders/
*  Myeloproliferative neoplasm - Wikipedia
2005). "A gain-of-function mutation of JAK2 in myeloproliferative disorders". N Engl J Med. 352 (17): 1779-1790. doi:10.1056/ ... The myeloproliferative neoplasms (MPNs), previously myeloproliferative diseases (MPDs), are a group of diseases of the bone ... Myeloproliferative Disorders at the US National Library of Medicine Medical Subject Headings (MeSH) ... 2005). "Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders". Lancet. 365 (9464): 1054-1061. ...
  https://en.wikipedia.org/wiki/Myeloproliferative_disease
*  Analysis of GATA1 mutations in Down syndrome transient myeloproliferative disorder and myeloid leukemia. - Department of...
... of newborns with DS develop transient myeloproliferative disorder (TMD). Blast cell structure and immunophenotype are similar ... Furthermore, no significant difference in the mutational spectrum between the 2 disorders was seen. Thus, the type of GATA1 ... Analysis of GATA1 mutations in Down syndrome transient myeloproliferative disorder and myeloid leukemia. ... Analysis of GATA1 mutations in Down syndrome transient myeloproliferative disorder and myeloid leukemia. ...
  https://www.paediatrics.ox.ac.uk/publications/163951
*  Clinical significance of neutrophil CD177 mRNA expression in Ph-negative chronic myeloproliferative disorders | IRIS UNIPV
Clinical significance of neutrophil CD177 mRNA expression in Ph-negative chronic myeloproliferative disorders. ... Clinical significance of neutrophil CD177 mRNA expression in Ph-negative chronic myeloproliferative disorders ... neutrophil CD177 mRNA levels in normal subjects and in 235 patients with Ph-negative chronic myeloproliferative disorders (CMD ... neutrophil CD177 mRNA levels in normal subjects and in 235 patients with Ph-negative chronic myeloproliferative disorders (CMD ...
  https://iris.unipv.it/handle/11571/115818
*  Myeloproliferative disorders | OncoLink
MPD means myeloproliferative disorder. In these patients, typically there is an increase in the number of cells being made by ... Myelodysplastic/ Myeloproliferative Neoplasms Treatment (PDQ®) (Health professionals) Chronic Myeloproliferative Neoplasms ... Depending on the specific manifestations of the patient's disorder as well as the results of additional testing that may be ... Could you please send me information on what the disorder is exactly? ...
  https://www.oncolink.org/frequently-asked-questions/cancers/leukemia/general-concerns/myeloproliferative-disorders
*  Mutation Linked to Myeloproliferative Disorders | Medpage Today
England-A single acquired mutation of the tyrosine kinase JAK2 gene may be responsible for a number of myeloproliferative ... disorders and could lead to new diagnostic and treatment approaches ... Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. The Lancet. 2005; 365:1054-1061. ... In a study comparing 140 patients with myeloproliferative disorders against 90 controls with type 1 diabetes, scientists at ...
  https://www.medpagetoday.com/hematologyoncology/leukemia/736
*  Myeloproliferative Disorders - Ferrell Quiz - By Sheppard
Can you name the Myeloproliferative Disorders - Ferrell? Test your knowledge on this literature quiz to see how you do and ... Myeloproliferative Disorders - Ferrell. Random Literature Quiz QUIZ: Can you name the Myeloproliferative Disorders - Ferrell?. ... uric acid can result in this GI disorder. lymphadenopathy is a late finding, associated with a poor prognosis of this disorder ... if a myelogenous disorder is going to progress, it is likely to progress into this. ...
  https://www.sporcle.com/games/Sheppard/ferrellday2
*  Blood and neoplastic diseases. Myeloproliferative disorders. | The BMJ
Myeloproliferative disorders.. Br Med J 1974; 4 doi: https://doi.org/10.1136/bmj.4.5941.399 (Published 16 November 1974) Cite ...
  http://www.bmj.com/content/4/5941/399
*  Myeloproliferative disorders: let the partner guide! | Haematologica
Myeloproliferative disorders: let the partner guide! Message Subject (Your Name) has forwarded a page to you from Haematologica ... Myeloproliferative disorders (MPD) are clonal proliferative diseases of the hematopoietic stem cell with expansion of one or ... 2006) Myeloproliferative disorders: premalignant, stem cell, G1 diseases? Leukemia 20:1475-80. ... 2005) PCM1-JAK2 fusion in myeloproliferative disorders and acute erythroid leukemia with t(8;9) translocation. Leukemia 19:1692 ...
  http://www.haematologica.org/content/92/6/728
*  Myeloproliferative Disorder - Facts, Symptoms, Diagnosis & Treatment | MD Anderson Cancer Center
Learn more about myeloproliferative disease symptoms and treatment today. ... MD Anderson Cancer Center is committed to myeloproliferative disorder research. ... What are myeloproliferative disorder's symptoms? Many times, especially in the early stages, myeloproliferative disorder does ... Myeloproliferative disorder treatments. Myeloproliferative disorder is often challenging to treat, and it may require years of ...
  https://www.mdanderson.org/cancer-types/myeloproliferative-disorder.html
*  Search of: Recruiting, Not yet recruiting, Available Studies | 'Myeloproliferative Disorders' - List Results - ClinicalTrials...
Also searched for Myeloproliferative disease and Myeloproliferative neoplasm. See Search Details. Applied Filters: Recruiting ... 299 Studies found for: Recruiting, Not yet recruiting, Available Studies , 'Myeloproliferative Disorders' ... Change in symptom score as measured by a modified myeloproliferative neoplasm symptom assessment form ...
  https://clinicaltrials.gov/ct2/results?recr=Open&cond=%22Myeloproliferative+Disorders%22&pg=2
*  Myeloproliferative disorder | Radiology Reference Article | Radiopaedia.org
Myeloproliferative disorders (MPDs) are a diverse group of conditions that are characterised by the overproduction of red cells ... Myeloproliferative disorder. Dr Avni K P Skandhan and Dr Henry Knipe ◉ ◈ et al. ... Myeloproliferative disorders (MPDs) are a diverse group of conditions that are characterised by the overproduction of red cells ...
  https://radiopaedia.org/articles/myeloproliferative-disorder
*  Diagnostic and therapeutic management of eosinophilia-associated chronic myeloproliferative disorders | Haematologica
2002) Myeloproliferative disorders with translocations of chromosome 5q31-35: role of the platelet-derived growth factor ... 2005) PCM1-JAK2 fusion in myeloproliferative disorders and acute erythroid leukemia with t(8;9) translocation. Leukemia 19:1692 ... 2007) Tyrosine kinases as therapeutic targets in BCR-ABL negative chronic myeloproliferative disorders. Current Drug Targets 8: ... 1995) A new myeloproliferative disorder associated with chromosomal translocations involving 8p11: a review. Leukemia 9:1628-30 ...
  http://www.haematologica.org/content/92/9/1153
*  Europe Myeloproliferative Disorders Clinical Trials Market Report 2016 - QY Research
Research Report on Europe Myeloproliferative Disorders Clinical Trials Market Report 2016. The Report includes market price, ... Table UK Myeloproliferative Disorders Clinical Trials Sales by Type (2015 and 2016). Table UK Myeloproliferative Disorders ... Figure UK Myeloproliferative Disorders Clinical Trials Sales Price Trend (2011-2016). Table UK Myeloproliferative Disorders ... Figure Picture of Myeloproliferative Disorders Clinical Trials. Table Classification of Myeloproliferative Disorders Clinical ...
  https://www.qyresearchreports.com/report/europe-myeloproliferative-disorders-clinical-trials-market-report-2016.htm
*  Global Myeloproliferative Disorders Clinical Trials Market Professional Survey Report 2016 - QY Research
Research Report on Global Myeloproliferative Disorders Clinical Trials Market Professional Survey Report 2016. The Report ... Global Myeloproliferative Disorders Clinical Trials Market Professional Survey Report 2016. Published On : Jun 2016 ... The report also provides an inclusive outlook of the elite companies operating in the Global myeloproliferative disorders ... and prospects present in the Global myeloproliferative disorders clinical trials market professional survey report 2016 market ...
  https://www.qyresearchreports.com/report/global-myeloproliferative-disorders-clinical-trials-market-professional-survey-report-2016.htm
*  Sex differences in the JAK2V617F allele burden in the chronic myeloproliferative disorders | Haematologica
When considering all patients with myeloproliferative disorders, women had significantly lower allele burdens than men (p=0.04 ... Sex differences in the JAK2V617F allele burden in the chronic myeloproliferative disorders ... Sex differences in the JAK2V617F allele burden in the chronic myeloproliferative disorders ... Sex differences in the JAK2V617F allele burden in the chronic myeloproliferative disorders ...
  http://www.haematologica.org/content/early/2010/02/04/haematol.2009.014407
*  Global Myeloproliferative Disorders Clinical Trials Market Research Report 2016 - QY Research
Research Report on Global Myeloproliferative Disorders Clinical Trials Market Research Report 2016. The Report includes market ... Table Global Myeloproliferative Disorders Clinical Trials Price by Type (2011-2016). Figure Global Myeloproliferative Disorders ... Figure Myeloproliferative Disorders Clinical Trials Market Share of Top 3 Manufacturers. Figure Myeloproliferative Disorders ... Figure Manufacturing Process Analysis of Myeloproliferative Disorders Clinical Trials. Figure Myeloproliferative Disorders ...
  https://www.qyresearchreports.com/report/global-myeloproliferative-disorders-clinical-trials-market-research-report-2016.htm
*  Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body...
Myelodysplastic syndromes/myeloproliferative disorders (MDS/MPD) - must have received previous myelosuppressive chemotherapy or ... Post-transplant Lymphoproliferative Disorder Previously Treated Myelodysplastic Syndromes Primary Myelofibrosis Prolymphocytic ...
  https://clinicaltrials.gov/ct2/show/NCT00089011?recr=Open&cond=%22Mycoses%22&rank=3

Myelodysplastic–myeloproliferative diseases: Myelodysplastic–myeloproliferative diseases are a category of hematological malignancies disorders created by the World Health Organization which have characteristics of both myelodysplastic and myeloproliferative conditions.Louis Henri Vaquez: Louis Henri Vaquez (27 August 1860 – 1936) was a French internist born in Paris. He is known for his work in the field of hematology and his research of heart disease.MyelofibrosisJanus kinase 2: Janus kinase 2 (commonly called JAK2) is a non-receptor tyrosine kinase. It is a member of the Janus kinase family and has been implicated in signaling by members of the type II cytokine receptor family (e.ThrombocytosisCongenital amegakaryocytic thrombocytopeniaMyelomonocyte: A myelomonocyte is a type of cell observed in chronic myelomonocytic leukemia. It bears a resemblance to both a myelocyte and monocyte.Blueberry muffin baby: Blueberry muffin baby is the characteristic distributed purpura occurring as a result of extramedullary hematopoiesis found in infants. The purpura are often generalized, but occur more often on the trunk, head, and neck.Chronic neutrophilic leukemiaBone marrow suppression: Bone marrow suppression or myelotoxicity (adjective myelotoxic) or myelosuppression is the decrease in production of cells responsible for providing immunity (leukocytes), carrying oxygen (erythrocytes), and/or those responsible for normal blood clotting (thrombocytes). Bone marrow suppression is a serious side effect of chemotherapy and certain drugs affecting the immune system such as azathioprine.Refractory cytopenia with multilineage dysplasiaMyeloid: The term myeloid (myelogenous) is an adjective that can refer to a progenitor cell for granulocytes, monocytes, erythrocytes, or platelets. Myeloid can be distinguished from the lymphoid progenitor cells that give rise to B cells and T cells.Granulocyte: framed|Eosinophilic granulocyteNational Down Syndrome SocietyMyeloid leukemiaSilent mutation: Silent mutations are mutations in DNA that do not significantly alter the phenotype of the organism in which they occur. Silent mutations can occur in non-coding regions (outside of genes or within introns), or they may occur within exons.PolycythemiaHepatosplenomegalyOncogene: An oncogene is a gene that has the potential to cause cancer.Wilbur, Beth, editor.Hypereosinophilic syndrome: (ILDS D72.12)LeukocytosisBudd–Chiari syndromeThrombopoietin: Thrombopoietin (THPO) also known as megakaryocyte growth and development factor (MGDF) is a protein that in humans is encoded by the THPO gene.Minimally differentiated acute myeloblastic leukemiaMissense mutation: In genetics, a missense mutation (a type of nonsynonymous substitution) is a point mutation in which a single nucleotide change results in a codon that codes for a different amino acid. Another type of nonsynonymous substitution is a nonsense mutation in which a codon is changed to a premature stop codon that results in truncation of the resulting protein.EML4-ALK positive lung cancer: EML4-ALK positive lung cancer is a medical term that refers to a primary malignant lung tumor whose cells contain a characteristic abnormal configuration of DNA wherein the echinoderm microtubule-associated protein-like 4 (EML4) gene is fused to the anaplastic lymphoma kinase (ALK) gene. This abnormal gene fusion leads to the production of a protein (EML4-ALK) that appears, in many cases, to promote and maintain the malignant behavior of the cancer cells.Hydroxyurea dermopathyBipolar disorderImatinibNon-communicable disease: Non-communicable disease (NCD) is a medical condition or disease that is non-infectious or non-transmissible. NCDs can refer to chronic diseases which last for long periods of time and progress slowly.Mental disorderLarge for gestational age: newborn child, delivered vaginally without complications (41 weeks; fourth child; no gestational diabetes) |Childhood leukemia: Childhood leukemia is a type of leukemia, usually acute lymphocytic leukemia (ALL), and a type of childhood cancer. The cure rate of childhood leukemia is generally higher than adult leukemia, approaching 90%, although some side effects of treatment last into adulthood.Blood cell: A blood cell, also called a hemocyte, hematocyte, or hematopoietic cell, is a cell produced through hematopoiesis and is normally found in blood. In mammals, these fall into three general categories:PyrazolopyrimidinePiperazineOrnithinaemia: Ornithinaemia is a blood disorder characterized by high levels of ornithine. Also known as hyperornithinemia, it may be associated with psychomotor retardation or epileptic episodes.Janus kinase inhibitor: Janus kinase inhibitors, also known as JAK inhibitors or jakinibs, are a type of medication that functions by inhibiting the activity of one or more of the Janus kinase family of enzymes (JAK1, JAK2, JAK3, TYK2), thereby interfering with the JAK-STAT signaling pathway. These inhibitors have therapeutic application in the treatment of cancer and inflammatory diseases.Social anxiety disorderPoint mutationTyrosine-kinase inhibitor: A tyrosine kinase inhibitor (TKI) is a pharmaceutical drug that inhibits tyrosine kinases. Tyrosine kinases are enzymes responsible for the activation of many proteins by signal transduction cascades.Valine N-monooxygenase: Valine N-monooxygenase (, CYP79D1, CYP79D2) is an enzyme with system name L-valine,NADPH:oxygen oxidoreductase (N-hydroxylating). This enzyme catalyses the following chemical reactionHematological Cancer Research Investment and Education Act: The Hematological Cancer Research Investment and Education Act of 2001 (P.L.Bone Marrow Transplantation (journal): Bone Marrow Transplantation is a peer-reviewed medical journal covering transplantation of bone marrow in humans. It is published monthly by the Nature Publishing Group.Fibroblast growth factor receptor 1: Fibroblast growth factor receptor 1 (FGFR1), also known as basic fibroblast growth factor receptor 1, fms-related tyrosine kinase-2 / Pfeiffer syndrome, and CD331, is a receptor tyrosine kinase whose ligands are specific members of the fibroblast growth factor family. FGFR1 has been shown to be associated with Pfeiffer syndrome.Overwhelming post-splenectomy infection: An overwhelming post-splenectomy infection (OPSI) is a rare but rapidly fatal infection occurring in individuals following removal of the spleen. The infections are typically characterized by either meningitis or sepsis, and are caused by encapsulated organisms including Streptococcus pneumoniae.Neurofibromin 1: Neurofibromin 1 also known as neurofibromatosis-related protein NF-1 is a protein that in humans is encoded by the NF1 gene. Mutations in the NF1 gene are associated with neurofibromatosis type I (also known as von Recklinghausen disease) and Watson syndrome.SchizophreniaPhenotype microarray: The phenotype microarray approach is a technology for high-throughput phenotyping of cells.Thermal cyclerGross pathology: Gross pathology refers to macroscopic manifestations of disease in organs, tissues, and body cavities. The term is commonly used by anatomical pathologists to refer to diagnostically useful findings made during the gross examination portion of surgical specimen processing or an autopsy.Platelet lysate: Human Platelet Lysate (or hPL) is a substitute supplement for fetal bovine serum (FBS) in experimental and clinical cell culture. It corresponds to a turbid, light-yellow liquid that is obtained from human blood platelets after freeze/thaw cycle(s).Genetic imbalance: Genetic imbalance is to describe situation when the genome of a cell or organism has more copies of some genes than other genes due to chromosomal rearrangements or aneuploidy.Type I cytokine receptor: Type I cytokine receptors are transmembrane receptors expressed on the surface of cells that recognize and respond to cytokines with four α-helical strands. These receptors are also known under the name hemopoietin receptors, and share a common amino acid motif (WSXWS) in the extracellular portion adjacent to the cell membrane.Continuous erythropoietin receptor activator: Continuous erythropoietin receptor activator (CERA) is the generic term for drugs in a new class of third-generation erythropoiesis-stimulating agents (ESAs). In the media, these agents are commonly referred to as 'EPO', short for erythropoietin.

(1/769) Mutant N-ras induces myeloproliferative disorders and apoptosis in bone marrow repopulated mice.

Mutations that activate the N-ras oncogene are among the most frequently detected genetic alterations in human acute myeloid leukemias (AMLs), Philadelphia chromosome-negative myeloproliferative disorders (MPDs), and myelodysplastic syndromes (MDSs). However, because N-ras has not been shown to induce these disorders in an in vivo model, the role of N-ras in the evolution of myeloid leukemia is unclear. To investigate the potential of N-ras to induce myeloid leukemia, lethally irradiated mice were reconstituted with bone marrow (BM) cells infected with a retroviral vector carrying activated N-ras. Approximately 60% of these mice developed hematopoietic disorders, including severe MPDs resembling human chronic myelogenous leukemia (CML) or AML with differentiation (French-American-British [FAB] classification M2). Other reconstituted mice succumbed to hematopoietic defects that were pathologically similar to human MDSs. The latter disorders appeared to be due to a myeloid impairment that was demonstrated by enumeration of day-12 colony-forming units-spleen (CFU-S) and by in vitro colony assays. A high level of apoptosis associated with thymic atrophy and peripheral blood (PB) lymphopenia was also evident in N-ras reconstituted mice. Our results are consistent with a model in which antiproliferative effects are a primary consequence of N-ras mutations and secondary transforming events are necessary for the development of myeloid leukemia. This is the first report of an in vivo model for N-ras induced MPD and leukemia.  (+info)

(2/769) Patients with thrombocytosis have normal or slightly elevated thrombopoietin levels.

BACKGROUND AND OBJECTIVE: The distinction between clonal and reactive thrombocytoses is a frequent problem and implies different therapeutic options. As thrombopoietin (TPO) is the main regulator of megakaryocytopoiesis and thrombopoiesis, we measured TPO levels in patients with thrombocytosis in an attempt to understand the regulation and potential utility of distinguishing thrombocytoses. DESIGN AND METHODS: Serum TPO levels, platelet counts, mean platelet volume, hemoglobin, erythrocyte sedimentation rate and age were evaluated in 25 patients with clonal thrombocytosis (15 with essential thrombocythemia, 6 with polycythemia vera and 4 with chronic myeloid leukemia) and in 50 patients with reactive thrombocytosis distributed in three groups: 1) patients in post-surgical states; 2) patients with solid tumors; and 3) patients with inflammatory diseases. RESULTS: TPO levels were slightly increased in patients with clonal (135+/-50 pg/mL) and reactive (147+/-58 pg/mL) thrombocytosis compared with controls (121+/-58 pg/mL). Analyzing the different groups, patients with essential thrombocythemia had the lowest TPO levels (120+/-28 pg/mL) and patients with solid tumors the highest levels (162+/-59 pg/mL). Patients with clonal thrombocytosis were older, had higher platelet counts, mean platelet volume and hemoglobin, and lower erythrocyte sedimentation rate than patients with reactive thrombocytosis. INTERPRETATION AND CONCLUSIONS: Minor differences were observed in TPO levels between patients with primary and secondary thrombocytoses. Erythrocyte sedimentation rate, but not TPO levels, may be a useful tool for discriminating both types of thrombocytoses.  (+info)

(3/769) Trisomy 21 associated transient neonatal myeloproliferation in the absence of Down's syndrome.

Although usually associated with Down's syndrome, transient neonatal myeloproliferation (TMD) can occur in the absence of a constitutional trisomy 21. This report describes two such cases, both of whom had a trisomy 21 restricted to clonal cells. Unlike in previous such reported cases, spontaneous morphological, cytogenetic, and molecular remission in both cases was followed by re-emergence, in one case, of an evolved clone with a more malignant phenotype which required pharmacological intervention. Awareness that trisomy 21 bearing leukaemia in the neonatal period can be transient even in the absence of Down's syndrome is important to prevent unnecessary treatment. Equally, such cases require indefinite follow up as a proportion may have a recurrence which may require treatment.  (+info)

(4/769) Characterization of FIM-FGFR1, the fusion product of the myeloproliferative disorder-associated t(8;13) translocation.

The t(8;13) translocation found in a rare type of stem cell myeloproliferative disorder generates a constitutively activated tyrosine kinase containing N-terminal sequence encoded by the FIM gene linked to the FGFR1 kinase domain. Here we have further characterized FIM and FIM-FGFR1 proteins. Firstly, we have studied their respective subcellular localization. We show that FIM has nuclear and nucleolar localization, whereas FIM-FGFR1 is mainly cytoplasmic. Within the nucleolus, FIM colocalizes with the upstream binding factor in interphasic cells, indicating that FIM may be involved in the regulation of rRNA transcription. We demonstrate that the targetting of FIM to the nucleus depends upon its C-terminal region, which is absent in the cytoplasmic FIM-FGFR1 protein. Secondly, we demonstrate that FIM-FGFR1 has constitutive dimerization capability mediated by the FIM N-terminal sequences. Finally, we show that FIM-FGFR1 promotes survival of pro-B Ba/F3 cells after interleukin-3 withdrawal, whereas ligand-activated FGFR1 induced not only cell survival but also interleukin-3 independence. Taken together, these results indicate that FIM-FGFR1 is activated by dimerization as a cytoplasmic kinase and suggest that FIM-FGFR1 partially signals through the FGFR1 pathways.  (+info)

(5/769) Bcr-Abl with an SH3 deletion retains the ability To induce a myeloproliferative disease in mice, yet c-Abl activated by an SH3 deletion induces only lymphoid malignancy.

The bcr-abl oncogene plays a critical role in the pathogenesis of chronic myelogenous leukemia (CML). The fusion of Bcr sequences to Abl constitutively activates the Abl protein tyrosine kinase. We have recently shown that expression of Bcr-Abl in bone marrow cells by retroviral transduction efficiently induces in mice a myeloproliferative disease resembling human CML and that Abl kinase activity is essential for Bcr-Abl to induce a CML-like myeloproliferative disease. However, it is not known if activation of the Abl kinase alone is sufficient to induce a myeloproliferative disease. In this study, we examined the role of the Abl SH3 domain of Bcr-Abl in induction of myeloproliferative disease and tested whether c-Abl activated by SH3 deletion can induce a CML-like disease. We found that Bcr-Abl with an Abl SH3 deletion still induced a CML-like disease in mice. In contrast, c-Abl activated by SH3 deletion induced only lymphoid malignancies in mice and did not stimulate the growth of myeloid colonies from 5-fluorouracil-treated bone marrow cells in vitro. These results indicate that Bcr sequences in Bcr-Abl play additional roles in inducing myeloproliferative disease beyond simply activating the Abl kinase domain and that functions of the Abl SH3 domain are either not required or redundant in Bcr-Abl-induced myeloproliferative disease. The results also suggest that the type of hematological neoplasm induced by an abl oncogene is influenced not only by what type of hematopoietic cells the oncogene is targeted into but also by the intrinsic oncogenic properties of the particular abl oncogene. In addition, we found that DeltaSH3 c-Abl induced less activation of Akt and STAT5 than did Bcr-Abl, suggesting that activation of these pathways plays a critical role in inducing a CML-like disease.  (+info)

(6/769) De novo appearance of the ph-1 chromosome in a previously monosomic bone marrow (45,XX,-6): conversion of a myeloproliferative disorder to acute myelogenous leukemia.

Bone marrow examination of a patient with a myeloproliferative disorder revealed monosomy for chromosome No. 6 (45,XX,-6). Two months later, during blastic crisis, reinvestigation of the bone marrow showed the presence of the Ph-1 chromosome in the previously aneuploid cell line (45,XX,-6,-22,+Ph-1). This case differs from those previously published in that the Ph-1 chromosome appeared de novo during the development of frank acute myelogenous leukemia.  (+info)

(7/769) Patients' psychosocial concerns following stem cell transplantation.

Information regarding the nature, frequency, correlates and temporal trajectory of concerns of stem cell transplantation (SCT) recipients is critical to the development of interventions to enhance quality of life (QOL) in these individuals. This study examined psychosocial concerns in 110 SCT (87% autologous) recipients drawn from two SCT centers. Participants were a mean of 46 years of age and 17 months post-SCT (range 3-62 months). Information regarding current and past SCT-related concerns, performance status, and demographic characteristics was collected by telephone interview or questionnaire. Recipients reported a wide variety of psychosocial concerns following SCT. Recipients who were younger, female and evidenced a poorer performance status reported a larger number of post-SCT concerns. Examination of the temporal trajectory of concerns suggests that some concerns are salient throughout the course of post-SCT recovery (eg disease recurrence, energy level, 'returning to normal'), some are salient early in the course of recovery (eg quality of medical care, overprotectiveness by others), and others emerge later in the course of recovery (eg feeling tense or anxious, sexual life, sleep, relationship with spouse/partner, ability to be affectionate). Implications for the development of interventions to enhance post-SCT QOL are identified.  (+info)

(8/769) Myeloproliferative disorders.

Forty-three operative procedures were performed on a population of 250 patients with myeloproliferative disorders, including polycythemia vera, myeloid metaplasia (MM) and chronic myelogenous leukemia (CML). The overall operative mortality was approximately 7% and the incidence of excessive bleeding which could be related to coagulopathy was 5%. Twenty-one patients with MM or CML underwent splenectomy for palliation of symptoms related to the enlarged spleen or hematologic problems. Eighty-four percent of the latter group were improved. Adverse hematologic effects which could be attributed to splenectomy in these patients were confined to two patients who developed marked thrombocytosis. Among the 23 patients with MM, 9 had portal hypertension. Three underwent portacaval shunt and one a splenorenal shunt for bleeding varices. One of the patients died of hepatic necrosis. Estimated hepatic blood flow determinations (EHBF) in 4 patients with portal hypertension demonstrated a marked absolute increase and an increase in the ratio of EHBF/Cardiac Index. Absence of any evidence of intrahepatic or extrahepatic obstruction in these patients and the demonstration that splenectomy relieved portal hypertension defined at surgery in 4 patients, suggests that augmented adhepatic flow contributes to portal hypertension in some cases. The review leads to the conclusions that: 1) Operative procedures in prepared patients with myeloproliferative disorders are not associated with prohibitive mortality and morbidity rates. 2) Splenectomy is indicated for patients with increasing transfusion requirements and symptomatic splenomegaly or hypersplenism and should be performed early in the course of disease. 3) When associated portal hypertension and bleeding varices are present, hemodynamic studies should be carried out to define if splenectomy alone, or a portal systemic decompressive procedure is indicated.  (+info)



  • chronic
  • Among these cancers are chronic neutrophilic leukemia (CNL) and atypical ( BCR-ABL1 -negative) chronic myeloid leukemia (CML), both of which are diagnosed on the basis of neoplastic expansion of granulocytic cells and exclusion of genetic drivers that are known to occur in other myeloproliferative neoplasms and myeloproliferative- myelodysplastic overlap neoplasms. (pubmedcentralcanada.ca)
  • Mr Duncan was diagnosed with Chronic Neutrophilic Leukaemia 20 years ago, a rare disorder which has no cure - there are only about 130 cases reported in the world. (thefreedictionary.com)
  • In one of the early descriptions of two cases (1), the authors concluded that this disorder was a variant of chronic myelogenous leukemia. (annals.org)
  • The recent introduction of chromosomal analysis has been helpful in distinguishing chronic myelogenous leukemia within the group of myeloproliferative disorders, as have cytochemical techniques. (annals.org)